Effects of neutrophil to lymphocyte ratio on short-term efficacy of FOLFOX hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2021年第5期
- Page:
- 602-605
- Research Field:
- 医学影像物理
- Publishing date:
Info
- Title:
- Effects of neutrophil to lymphocyte ratio on short-term efficacy of FOLFOX hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
- Author(s):
- WU Lingeng1; 2; CHEN Meng1; GOU Qing1; MAI Qicong1; ZHOU Zejian1
- 1. Department of Interventional Therapy, Cancer Center, Guangdong Provincial Peoples Hospital (Guangdong Academy of Medical Sciences), Guangzhou 510080, China 2. Medical College of Shantou University, Shantou 515041, China
- Keywords:
- Keywords: hepatocellular carcinoma neutrophil lymphocyte FOLFOX transcatheter arterial infusion chemotherapy
- PACS:
- R735.7
- DOI:
- DOI:10.3969/j.issn.1005-202X.2021.05.015
- Abstract:
- Abstract: Objective To investigate the effects of neutrophil to lymphocyte ratio (NLR) on the short-term therapeutic efficacy of FOLFOX hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (HCC). Methods A total of 92 patients with advanced HCC treated by FOLFOX hepatic arterial infusion chemotherapy from May 2017 to March 2019 were enrolled in the study. CT or MR was used to compare the local tumor response after each treatment cycle, and the therapeutic efficacy and safety of hepatic arterial perfusion were evaluated by relevant examination results and clinical symptoms. Results The intrahepatic lesions were evaluated according to mRECIST criteria. The objective response rate of NLR<4.0 group was significantly higher than that of NLR≥4.0 group (41.5% vs 17.9%, P=0.016). The disease control rate of NLR<4.0 group was also superior to that of NLR≥4.0 group (52.8% vs 28.2%, P=0.018). For intrahepatic lesions, the median progression free survival (PFS) in NLR<4.0 group was longer than that in NLR≥4.0 group (6.1 months vs 4.1 months, P=0.013) and the evaluation of the therapeutic efficacy of systemic tumor lesions showed that the median PFS was also significantly different between NLR<4.0 group and NLR≥4.0 group (4.3 months vs 3.1 months, P=0.022). Conclusion FOLFOX hepatic arterial infusion is safe and effective in treating HCC, and NLR is an indicator to predict the therapeutic efficacy of HCC perfusion chemotherapy. Patients with high NLR before surgery have shorter PFS after treatment.
Last Update: 2021-05-31